Results 41 to 50 of about 5,317,572 (397)

DNA-PK Mediates AKT Activation and Apoptosis Inhibition in Clinically Acquired Platinum Resistance

Neoplasia: An International Journal for Oncology Research, 2011
Clinical resistance to chemotherapy is a frequent event in cancer treatment and is closely linked to poor outcome. High-grade serous (HGS) ovarian cancer is characterized by p53 mutation and high levels of genomic instability. Treatment includes platinum-
Euan A. Stronach, Michelle Chen, Elaina N. Maginn, Roshan Agarwal, Gordon B. Mills, Harpreet Wasan, Hani Gabra   +6 more
doaj   +1 more source

EOCSA: Predicting Prognosis of Epithelial Ovarian Cancer with Whole Slide Histopathological Images [PDF]

, 2022
Ovarian cancer is one of the most serious cancers that threaten women around the world. Epithelial ovarian cancer (EOC), as the most commonly seen subtype of ovarian cancer, has rather high mortality rate and poor prognosis among various gynecological cancers. Survival analysis outcome is able to provide treatment advices to doctors.
arxiv   +1 more source

Ovarian cancer symptom awareness and anticipated delayed presentation in a population sample [PDF]

, 2014
Background: While ovarian cancer is recognised as having identifiable early symptoms, understanding of the key determinants of symptom awareness and early presentation is limited.
A Bandura, AAPOR, AE Simon, AE Simon, AE Simon, AJ Ramirez, Alice E Simon, BA Goff, BA Goff, C Bankhead, C Maringe, CC Burgess, Ceri White, Chris Roberts, E Grunfeld, EL Low, EM Smith, Iain J Robbé, IM Rosenstock, J Evans, J Hippisley-Cox, J Wardle, Jane Hanson, JL Hay, John Steward, K Robb, Kate E Brain, L Rizzo, Lindsay J Forbes, LJL Forbes, LK Smith, MA Richards, MA Richards, MH Becker, MP Coleman, MR Andersen, MR Andersen, MR Andersen, MR Andersen, National Institute for Health and Clinical Excellence (NICE) guidance, P Sheeran, PM Gollwitzer, RD Neal, Richard D Neal, RS Andersen, S Quaife, S Stubbings, S Tyndel, SE Scott, Stephanie Smits, U Macleod, U Menon, W Hamilton, XD Brouha   +53 more
core   +2 more sources

Are GPs under-investigating older patients presenting with symptoms of ovarian cancer? Observational study using General Practice Research Database [PDF]

, 2010
Background: Recent studies suggest that older patients in the United Kingdom are not benefiting as much from improvements in cancer treatments as their younger counterparts.
A Majeed, A Moran, A Nicholson, A Quaglia, A R Tate, AL Hansell, C Bouchardy, C Falandry, F Berrino, J A Cassell, J Adams, J De Rijke, JMJ Kirwan, K Haynes, M Peake, N Turner, R Jones, R Neal, R Robertson, SW Pascoe, VL Allgar, W Hamilton   +21 more
core   +3 more sources

Ovarian and cervical cancer awareness: development of two validated measurement tools. [PDF]

, 2011
The aim of the study was to develop and validate measures of awareness of symptoms and risk factors for ovarian and cervical cancer (Ovarian and Cervical Cancer Awareness Measures)
Corker, E, Grimmett, C, Matheson, L, Menon, U, Power, E, Simon, AE, Waller, J, Wardle, J   +7 more
core   +1 more source

MS: Wip1 suppresses angiogenesis through the STAT3-VEGF signalling pathway in serous ovarian cancer

Journal of Ovarian Research, 2022
Multifaceted functions of the so-called “oncogene” Wip1 have been reported in a previous study, while its actual role remains to be explored in serous ovarian cancer (SOC).
Sheng Yin, Lina Yang, Yiyan Zheng, Rongyu Zang   +3 more
doaj   +1 more source

Advocacy in Action: Leveraging the Power of Patient Voices to Impact Ovarian Cancer Outcomes in Canada

Current Oncology, 2022
Prior to 1997, ovarian cancer (OC) was a ‘poor target’ for patient advocacy. At that time, there were only three OC researchers in Canada, little information available for women diagnosed, and no community of survivors existed.
Elisabeth Baugh, Alicia Tone, Talin Boghosian, Alison Ross, Cailey Crawford   +4 more
doaj   +1 more source

ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease

International Journal of Gynecological Cancer, 2019
The development of guidelines is one of the core activities of the European Society for Medical Oncology (ESMO) and European Society of Gynaecologial Oncology (ESGO), as part of the mission of both societies to improve the quality of care for patients ...
N. Colombo, N. Colombo, C. Sessa, A. Bois, J. Ledermann, W. McCluggage, I. McNeish, P. Morice, S. Pignata, I. Ray-Coquard, I. Vergote, T. Baert, I. Belaroussi, A. Dashora, S. Olbrecht, F. Planchamp, D. Querleu   +16 more
semanticscholar   +2 more sources

The role of epithelial-to-mesenchymal plasticity in ovarian cancer progression and therapy resistance [PDF]

, 2019
Ovarian cancer is the most lethal of all gynecologic malignancies and the eighth leading cause of cancer-related deaths among women worldwide. The main reasons for this poor prognosis are late diagnosis; when the disease is already in an advanced stage ...
Berx, Geert, Denys, Hannelore, Loret, Nele, Tummers, Philippe   +3 more
core   +2 more sources

Distinct histopathological features are associated with molecular subtypes and outcome in low grade serous ovarian carcinoma

Scientific Reports, 2023
Low grade serous ovarian carcinoma (LGSOC) demonstrates unique clinical and molecular features compared to other ovarian cancer types. The relationship between common histological features of LGSOC and molecular events, such as hormone receptor ...
Robert L. Hollis, John P. Thomson, Juliette van Baal, Narthana Ilenkovan, Michael Churchman, Koen van de Vijver, Frederike Dijk, Alison M. Meynert, Clare Bartos, Tzyvia Rye, Ian Croy, Patricia Diana, Mignon van Gent, Helen Creedon, Rachel Nirsimloo, Christianne Lok, Charlie Gourley, C. Simon Herrington   +17 more
doaj   +1 more source